John G Ullman & Associates Inc. Has $3.12 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

John G Ullman & Associates Inc. cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,814 shares of the medical research company’s stock after selling 130 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Amgen were worth $3,115,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. OFI Invest Asset Management bought a new stake in shares of Amgen during the 3rd quarter worth $26,000. Briaud Financial Planning Inc bought a new position in shares of Amgen during the third quarter worth about $26,000. Strategic Investment Solutions Inc. IL bought a new position in shares of Amgen during the first quarter worth about $28,000. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen during the fourth quarter worth about $29,000. Finally, Providence Capital Advisors LLC bought a new position in shares of Amgen during the third quarter worth about $30,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of AMGN traded up $6.18 during mid-day trading on Friday, hitting $268.93. The stock had a trading volume of 3,375,088 shares, compared to its average volume of 2,843,533. The firm has a market cap of $144.12 billion, a P/E ratio of 21.22, a PEG ratio of 2.46 and a beta of 0.58. The business has a fifty day moving average price of $277.34 and a 200-day moving average price of $281.24. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same period in the previous year, the company posted $4.09 earnings per share. The business’s revenue was up 19.8% on a year-over-year basis. On average, equities research analysts expect that Amgen Inc. will post 19.45 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.35%. Amgen’s payout ratio is 72.06%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. TD Cowen lowered their target price on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday. Daiwa Capital Markets upgraded Amgen from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $264.00 to $320.00 in a report on Thursday, December 21st. Morgan Stanley lowered their target price on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Finally, SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.